Existing Partners
Below you will find a list of our existing partners.
At the start of 2012, we announced a collaboration with Roquette, covering joint research and development of novel and optimised biosynthetic production routes for an ingredient with important applications in food products. Roquette is a world leader in the area of nutrition and other products based on raw vegetable materials. The collaboration will run for up to 4.5 years and involve c. 7% of Evolva’s R&D headcount.
Evolva is a member of a group of European companies and academic institutions (DIABAT), researching the role of brown adipose tissue (BAT) in the prevention and treatment of obesity and type 2 diabetes. Type 2 diabetes and its associated cardio-vascular complications have emerged as the leading causes of death in Western countries, associated with estimated health care costs of more than 30 billion Euros in the European Union per year. The DIABAT project will run for 4 years and is part-funded by the European Commission within the FP-7 programme.
In March 2011, Evolva signed an agreement with BASF for joint research on the design of novel and optimised biosynthesis routes for selected natural products with crop protection potential. This is Evolva’s first collaboration in which its technology is applied to the agricultural sector. BASF is the world’s leading chemical company with sales of EUR 63.9 billion in 2010.
The programme has the potential to reach predefined milestones in 2012.
In January 2011 Evolva announced a collaboration and joint development agreement with International Flavors & Fragrances Inc. (IFF), one of the world’s leading creators and manufacturers of flavours and fragrances for consumer products. The objective of the collaboration is to implement a commercially viable biosynthetic route for the production of a key flavouring ingredient. The project is progressing as planned and has the potential to reach a milestone in 2012.
In May 2012, the collaboration was expanded to include an additional flavouring ingredient.
Under both agreements, IFF is funding research and development projects at Evolva, focused primarily on pathway discovery and yield stages, through the scale-up and manufacturing phases. Evolva has received upfront payments and receives monthly research fees. Furthermore, Evolva will receive royalty on product sales based on both margin and volume.
The discovery collaboration with Roche, initiated in 2010, focuses on targets in oncology and anti-infectives. During the collaboration Evolva has created numerous novel compounds with drug-like properties. Some of these show promising activity against a range of viruses, others against protein:protein interactions relevant for oncology. In the course of 2011, selected early leads reached a stage where Roche took over responsibility of their further evaluation. Based on this achievement Roche made a second milestone payment to Evolva in November 2011. An earlier milestone was paid by Roche in June 2011.
Evolva aims to find approaches for a commercially viable and environmentally acceptable production of vanillin as part of the application of its synthetic biology platform to “white” biotechnology (the application of biotechnology for industrial purposes).
In DIVINOCELL (an EC-funded FP7 initiative) Evolva is part of a consortium of companies and academic laboratories. The goal of the program is to find compounds that curb the proliferation and viability of Gram-negative bacterial pathogens by inhibiting their machinery for cell division. Further information on this program can be found at http://www.cnb.csic.es/~divinocell/.
What we offer
Nutrition & Consumer
Pharmaceuticals
Technology
